Mineralys Therapeutics, Inc. (MLYS)
25.22
-0.38
(-1.46%)
USD |
NASDAQ |
Aug 31, 14:08
Mineralys Therapeutics Cash from Investing (Quarterly) : -185.22M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -185.22M |
| March 31, 2026 | -44.94M |
| December 31, 2025 | -103.49M |
| September 30, 2025 | -150.51M |
| June 30, 2025 | -42.88M |
| March 31, 2025 | -92.88M |
| December 31, 2024 | 83.57M |
| September 30, 2024 | 79.60M |
| June 30, 2024 | 7.736M |
| Date | Value |
|---|---|
| March 31, 2024 | -55.95M |
| December 31, 2023 | -8.089M |
| September 30, 2023 | 4.007M |
| June 30, 2023 | -16.14M |
| March 31, 2023 | -140.25M |
| December 31, 2022 | 50.00M |
| September 30, 2022 | -71.76M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | 60.70M |
| Evommune, Inc. | 31.29M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -32.56M |
| Cash from Financing (Quarterly) | 243.26M |
| Free Cash Flow | -138.80M |
| Free Cash Flow Per Share (Quarterly) | -0.3842 |
| Free Cash Flow to Equity (Quarterly) | -130.17M |
| Free Cash Flow to Firm (Quarterly) | -32.56M |
| Free Cash Flow Yield | -6.91% |